Bayer and Regeneron Explore Combination Eye Treatment

31.03.2016 - Bayer and US drug developer Regeneron Pharmaceuticals have agreed to jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and vascular endothelial...